<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952818</url>
  </required_header>
  <id_info>
    <org_study_id>M2019460</org_study_id>
    <nct_id>NCT04952818</nct_id>
  </id_info>
  <brief_title>The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine</brief_title>
  <official_title>Radiomics Based on Preoperative Imaging of Giant Cell Tumor of the Spine to Predict the Early Recurrence and Survival of Giant Cell Tumor of the Spine After Surgery, and the Expression Levels of P53, VEGF, RANK, RANKL and Other Prognostic-related Molecular Markers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Exploit CT (plain scan), enhanced CT and fMRI based radiomic biomarkers, explore their&#xD;
           correlation with the prognostic molecular markers of spinal GCTB(p53/vegf/rank/rankl…),&#xD;
           and help accurate diagnosis of GCTB.&#xD;
&#xD;
        2. Exploring a new method of preoperative risk stratification for spinal GCTB, and&#xD;
           establishing radiomic model combined with clinical features. Exploring the GCTB&#xD;
           biological behavior prediction model and the prognosis prediction of GCTB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study intends to conduct a systematic review of patients with spinal GCTB who have&#xD;
      undergone standardized imaging (CT or MRI) in our hospital since 2006 to obtain case samples,&#xD;
      conduct standardized clinical and imaging data extraction and analysis, and fully integrate&#xD;
      histopathology and clinical follow-up results. To preliminarily explore the value of&#xD;
      postoperative imaging-based radiomics markers in the preoperative precise diagnosis of spinal&#xD;
      GCTB, risk stratification and prediction of tumor biological behavior.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RANK/RANKL</measure>
    <time_frame>2020</time_frame>
    <description>Grade:low;high(Receptor Activator of Nuclear factor Kappa-Β/Ligand)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF</measure>
    <time_frame>2020</time_frame>
    <description>Grade:low;high(Vascular Endothelial Growth Factors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>p53</measure>
    <time_frame>2020</time_frame>
    <description>Grade:low;high(Tumor Suppressor Protein)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>2020</time_frame>
    <description>recurrence group/non-recurrence group</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Spinal Tumor</condition>
  <arm_group>
    <arm_group_label>RANK/RANKL low expression</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>RANK/RANKL high expression</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)</intervention_name>
    <description>Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).</description>
    <arm_group_label>RANK/RANKL high expression</arm_group_label>
    <arm_group_label>RANK/RANKL low expression</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with spinal GCTB&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with spinal GCTB who underwent surgical resection or biopsy without&#xD;
             preoperative chemotherapy or radiotherapy were included in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  i) The CT scan was performed more than 1 week before surgery ii) Poor image quality.&#xD;
             Such as surrounding structure artifacts; iii) The remaining tumor tissue in the&#xD;
             postoperative paraffin specimen is too little to be used for reanalysis; iv) Cases&#xD;
             with negative H3F3A (H3 histone, family 3A) staining were excluded; v) Incomplete&#xD;
             clinical information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ning Lang</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University third hospital</name>
      <address>
        <city>Beijing</city>
        <state>Please Select An Option Below</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>giant cell tumor of bone</keyword>
  <keyword>radiomics</keyword>
  <keyword>recurrence</keyword>
  <keyword>spine tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Giant Cell Tumors</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
    <mesh_term>Spinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

